Silver Book Fact

Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.

Fleurence R, Iglesias C, Johnson J. The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature. PharmacoEcon. 2007; 25(11): 913-33. http://www.ncbi.nlm.nih.gov/pubmed/17960951

Reference

Title
The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature
Publication
PharmacoEcon
Publication Date
2007
Authors
Fleurence R, Iglesias C, Johnson J
Volume & Issue
Volume 25, Issue 11
Pages
913-33
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • A meta-analysis of clinical trials found that Vitamin D supplements reduced the risk of vertebral fractures by around 37%.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
  • 50% of Repeat Osteoporotic Fractures Could be Avoided